Navigation Links
Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
Date:11/5/2010

SEATTLE, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the Credit Suisse 2010 Health Care Conference, Phoenix, AZ on November 11, 2010 at 1:30 p.m. ET.

The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.  If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... ... a new market research report is available in its ... Market Perspective , http://www.reportlinker.com/p0164258/Cardiac-Biomarkers---A-Global-Market-Perspective.html , ... served as primary growth drivers for cardiac biomarkers market, ...
... , ... announces that a new market research report is available ... A Global Market Review , http://www.reportlinker.com/p0164337/Radiation-Therapy-Equipment---A-Global-Market-Review.html ... of new cancer cases diagnosed each year. Radiation therapy ...
Cached Medicine Technology:Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... developed at Brown University, promises to improve our understanding of ... tomography, or CT, delivers detailed 3-D images, but CT scanners ... that uses X-rays to view objects, can produce moving images ... surgeon trying to figure out the best way to repair ...
... All India Institute of Medical Sciences (AIIMS) director P. ... public relation officer filed a police complaint against him. ... relation officer of AIIMS, has filed a police complaint ... accusing Venugopal of harassment, wrongful restraint from entering office, ...
... is obviously a difficult question to answer. //There is no ... research that this is a fast growing and potentially widespread ... funded national stem cell depository would allow unfettered access for ... in the future. Unfortunately parents come to us because that ...
... want to help smokers kick ‘butts’; keep all warnings// printed ... ,The UN’s World Health Organization (WHO) identifies smoking ... ,It is responsible for the death of one in 10 ... , The researchers led by David Hammond, Ph.D., of ...
... campaign pointing out the threat of losing vision due ... young population//. This was cited by the British Journal ... Institute of the Blind, losing vision is considered more ... stroke and lung cancer associated with it. Hence the ...
... even today. But whether patients survive cancer seems to depend ... to spend// on the drugs, according to a Canadian report. ... treatment, and some Canadians will live and some will die ... Coalition of Canada report. ,The latest cancer treatments ...
Cached Medicine News:Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:Statutory Warnings on Cigarette Packs- Make It Bigger and Brighter, Say Researchers 2Health News:Call for a National 'Drugs Funding Program' for Cancer Treatment in Canada 2
... frames are designed with the safety and comfort ... Schott RS-520 (also called SF-6) leaded glass, the ... meet standards, as set for optical clarity, visible ... our eyewear is protecting your eyes, it also ...
... Protection Goggles fit over ... used by the whole ... glass, 1.0 mm leaded ... increased scatter radiation protection. ...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Medicine Products: